• Vaccine Name: Classical swine fever virus E1 protein vaccine
• Target Pathogen: Classical swine fever virus
• Target Disease: Classical swine fever, hog cholera
• Vaccine Ontology ID: VO_0011509
• Type: Subunit vaccine
• Status: Research
• Antigen: Classical swine fever virus gp55 encoding E1
• gp55 gene engineering:
  • Type: Recombinant protein preparation
  • Description: A recombinant virus BacEl[-], which expressed El without a C-terminal TMR, generated a protein that was secreted from the cells. The fraction of this protein that was found to be cell associated had a slightly lower molecular mass (49 to 52 kDa) than wild-type El and remained endo H sensitive. The high-mannose units of the secreted protein were trimmed during transport through the exocytotic pathway to endo H-resistant glycans, resulting in a protein with a lower molecular mass (46 to 48 kDa) (Hulst et al., 1993).
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)

Pig Response

• Vaccination Protocol: Groups of two specific-pathogen-free, 10- to 12-week-old pigs were inoculated intramuscularly with a double water-oil emulsion of immunoaffinity-purified El on day 0. Pigs 1, 2, 3, and 4 were inoculated with 20 ug of El, and pigs 6, 7, 8, and 9 were inoculated with 100 ug of El. After 28 days, pigs 3 and 4 were vaccinated again with 20 ug and pigs 8 and 9 were vaccinated with 100 ug of immunoaffinity-purified El. Pigs 5 and 10 (control pigs) were inoculated on day 0 with a double water-oil emulsion of SF900 medium from Sf21 cells infected with wild-type AcNPV and vaccinated again with the same inoculum on day 28 (Hulst et al., 1993).
• Challenge Protocol: Pigs of all groups were challenged intranasally on day 42 with 100 50% lethal doses of HCV strain Brescia 456610, a challenge dose that, in unprotected pigs, leads to acute disease characterized by high fever and thrombocytopenia starting at days 3 to 5 and to death at days 7 to 11(Hulst et al., 1993).
• Efficacy: Intramuscular vaccination of pigs with immunoaffinity-purified E1 (gp55) in a double water-oil emulsion elicited high titers of neutralizing antibodies between 2 and 4 weeks after vaccination at the lowest dose tested (20 micrograms). The vaccinated pigs were completely protected against intranasal challenge with 100 50% lethal doses of HCV (Classical swine fever virus) strain Brescia (Hulst et al., 1993).